Multivariate analysis of recurrence and progression in stage T1 transitional cell bladder carcinoma. Prognostic value of p53 and ki67;Análisis multivariado de recidiva y progresión en el carcinoma de células transicionales de vejiga en estadio T1. Valor pronóstico de p53 y ki67

Actas Urologicas Espanolas

Volumn 27, Issue 2, 2003, Pages 132-141

  Rodriguez Alonso A ^a   Pita Fernandez S ^b   Gonzalez Carrero J ^c   Nogueira March, J L ^c  

^a Universidad de La Coruña   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

Author keywords

Bladder neoplasm; ki67; p53; Prognosis; Progression; Recurrence

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIVARIATE ANALYSIS; PROGNOSIS; TRANSITIONAL CELL CARCINOMA;

EID: 12244283072     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(03)72891-5     Document Type: Article

References (19)

1. WITJES JA, KIEMENEY LALM, SCHAAFSMA HE, DEBRUYNE FMJ: The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Br J Urol 1994; 73: 172-176.
2. HERMANN GG, HORN T, STEVEN K: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998; 159: 91-94.
3. LINDEN MD, NATHANSON SD, ZARBO RJ: Evaluation of anti-p53 antibody staining. Quality control and technical considerations. Appl Immunohistochem 1994; 2 (3): 218-224.
4. MOSTOFI FK, SOBIN LH, TORLANI H: Histological typing of urinary bladder tumors. En International Histological Classification of Tumours. N° 10: Geneva: World Health Organization, 1973.
5. a Edición en Inglés. Berlin, Heidelberg: Springer-Verlag; 1997: 263-326.
6. ALLARD P, BERNARD P, FRADET Y, TÊTU B: The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692-698.
7. WITJES JA, KIEMENEY LALM, VERBEEK ALM, HEIJBROEK RP, DEBRUYNE FMJ: Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients. World J Urol 1992; 10: 231-234.
8. PFISTER C, LACOMBE L, VEZINA MC, MOORE L, LARUE H, TÊTU B, et al: Prognostic value of the proliferative index determined by ki67 immunostaining in superficial bladder tumors. Hum Pathol 1999; 11: 1350-1355.
9. OJEA-CALVO A, PÉREZ-GARCÍA MD, RODRÍGUEZ-ALONSO A, DOMÍNGUEZ-FREIRE F, ALONSO-RODRIGO A, RODRÍGUEZ IGLESIAS B, et al: Cáncer superficial de vejiga: ¿qué controles han de seguir y durante cuanto tiempo, los pacientes libres de tumor?. Actas Urol Esp 1998; 22: 210-214.
10. MILLÁN-RODRÍGUEZ F, CHÉCHILE-TONIOLO G, SALVADOR-BAYARRI J, PALOU J, VICENTE-RODRÍGUEZ J: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-78.
11. KIEMENEY LALM, WITJES JA, HEIJBROEK RP, VERBEEK ALM, DEBRUYNE FMJ: Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 60-64.
12. MILLÁN-RODRÍGUEZ F, CHECHILE-TONIOLO G, SALVADOR-BAYARRI J, HUGUET-PÉREZ J, VICENTE-RODRÍGUEZ J: Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 2000; 164: 1.183-1.187.
13. SCHMITZ-DRÄGER BJ, KUSHIMA M, GOEBELL P, JAX TW, GERHARZ CD, BÜLTEL H, et al: p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997; 32: 487-493.
14. LIUKKONEN T, RAJALA P, RAITANEN M, RINTALA E, KAASINEN E, LIPPONEN P: Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. Eur Urol 1999; 36: 393-400.
15. EPSTEIN JI, AMIN MB, REUTER VR, MOSTOFI FK: The bladder consensus conference committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22: 1.435-1.438.
16. GONTERO P, CASETTA G, ZITELLA A, BALLARIO R, PACCHIONI D, MAGNANI C, et al: Evaluation of p53 protein overexpression, ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional carcinoma of the bladder. Eur Urol 2000; 38: 287-296.
17. WAF1/CIP1 and ki67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guérin intravesical therapy. J Urol 1999; 161: 792-798.
18. LACOMBE L, DALBAGNI G, ZHANG ZF, CORDÓN-CARDO C, FAIR WR, HERR HW, et al: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol 1996; 14: 2646-2652.
19. SERTH J, KUCZYK MA, BOKEMEYER C, HERVATIN C, NAFE R, TAN HK, et al: p53 immunohistochemistry as an independent prognostic factor for superficial cell carcinoma of the bladder. Br J Cancer 1995; 71: 201-205.